We advised the underwriters on the IPO and Nasdaq listing

Davis Polk advised the underwriters in connection with the $258.8 million initial public offering of 17,250,000 common shares of ATAI Life Sciences N.V. (“ATAI”), which includes 2,250,000 shares from the full exercise of the underwriters’ option to purchase additional shares. ATAI is listed on the Nasdaq Global Market under the symbol “ATAI.”

ATAI is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. ATAI was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Roshni Banker Cariello, counsel Alain Kuyumjian and associates Ernesto Talamás Velázquez and Chan Tov McNamarah. Partner David R. Bauer and associates Christopher C. Woller and Shuang Ci provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Counsel Sarah E. Kim provided 1940 Act advice. The members of the Davis Polk team are based in the New York and São Paulo offices.

Copy link to share post